Utility of serum complement factors C3 and C4 as biomarkers during therapeutic management of giant cell arteritis

References

• Lane SE, Watts R, Scott DG. Epidemiology of systemic vasculitis. Curr Rheumatol Rep 2005;7:270–5.
   PubMedGoogle Scholar
• Salvarani C, Cantini F, Hunder GG. Polymyalgia rheumatica and giant-cell arteritis. Lancet 2008;372:234–45.
   PubMed Web of Science ®Google Scholar
• Prior JA, Ranjbar H, Belcher J, Mackie SL, Helliwell T, Liddle J, et al. Diagnostic delay for giant cell arteritis - a systematic review and meta-analysis. BMC Med 2017;15:120.
   PubMed Web of Science ®Google Scholar
• González-Gay MA, García-Porrúa C, Llorca J, Hajeer AH, Brañas F, Dababneh A, et al. Visual manifestations of giant cell arteritis. Trends and clinical spectrum in 161 patients. Medicine (Baltimore) 2000;79:283–92.
   PubMed Web of Science ®Google Scholar
• Unizony SH, Bao M, Han J, Luder Y, Pavlov A, Stone JH. Treatment failure in giant cell arteritis. Ann Rheum Dis 2021;80:1467–74.
   PubMed Web of Science ®Google Scholar
• Schmidt J, Smail A, Roche B, Gay P, Salle V, Pellet H, et al. Incidence of severe infections and infection-related mortality during the course of giant cell arteritis: a multicenter, prospective, double-cohort study. Arthritis Rheumatol 2016;68:1477–82.
   PubMed Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of Tocilizumab in giant-cell arteritis. N Engl J Med 2017;377:317–28.
   PubMed Web of Science ®Google Scholar
• Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020;79:19–30.
   PubMed Web of Science ®Google Scholar
• Pulsatelli L, Boiardi L, Assirelli E, Pazzola G, Muratore F, Addimanda O, et al. Imbalance between angiogenic and anti-angiogenic factors in sera from patients with large-vessel vasculitis. Clin Exp Rheumatol 2020;38:23–30.
   PubMed Web of Science ®Google Scholar
• Adler S, Reichenbach S, Gloor A, Yerly D, Cullmann J, Villiger PM. Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis. Rheumatology (Oxford) 2019;58:1639–43.
   PubMed Web of Science ®Google Scholar
• Sammel AM, Xue M, Karsten E, Little CB, Smith S, Nguyen K, et al. Limited utility of novel serological biomarkers in patients newly suspected of having giant cell arteritis. Int J Rheum Dis 2021;24:781–8.
   PubMed Web of Science ®Google Scholar
• Ehlers L, Askling J, Bijlsma HW, Cid MC, Cutolo M, Dasgupta B, et al. 2018 EULAR recommendations for a core data set to support observational research and clinical care in giant cell arteritis. Ann Rheum Dis 2019;78:1160–6.
   PubMed Web of Science ®Google Scholar
• Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122–8.
   PubMed Web of Science ®Google Scholar
• Unizony SH, Dasgupta B, Fisheleva E, Rowell L, Schett G, Spiera R, et al. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol 2013;2013:912562.
   PubMedGoogle Scholar
• Vaith P, Maas D, Von Stackelberg G, Peter HH. A new serological reaction in patients with polymyalgia rheumatica and/or giant cell (temporal) arteritis: deposition of complement C4 and C3 components on rat kidney structures detected by indirect immunofluorescence. Rheumatol Int 1986;6:255–61.
   PubMed Web of Science ®Google Scholar
• Chen R, Ma L, Lv P, Lin J, Li C, Yan Y, et al. Serum complement 3 is a potential biomarker for assessing disease activity in Takayasu arteritis. Arthritis Res Ther 2021;23:63.
   PubMed Web of Science ®Google Scholar
• Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Glucocorticoid dosages and acute-phase reactant levels at giant cell arteritis flare in a randomized trial of Tocilizumab. Arthritis Rheumatol 2019;71:1329–38.
   PubMed Web of Science ®Google Scholar
• Spiera R, Unizony SH, Bao M, Luder Y, Han J, Pavlov A, et al. Tocilizumab vs placebo for the treatment of giant cell arteritis with polymyalgia rheumatica symptoms, cranial symptoms or both in a randomized trial. Semin Arthritis Rheum 2021;51:469–76.
   PubMed Web of Science ®Google Scholar
• Romano C, Del Mastro A, Sellitto A, Solaro E, Esposito S, Cuomo G. Tocilizumab reduces complement C3 and C4 serum levels in rheumatoid arthritis patients. Clin Rheumatol 2018;37:1695–700.
   PubMed Web of Science ®Google Scholar
• Berman S, Gewurz H, Mold C. Binding of C-reactive protein to nucleated cells leads to complement activation without cytolysis. J Immunol 1986;136:1354–9.
   PubMed Web of Science ®Google Scholar
• Kaplan MH, Volanakis JE. Interaction of C-reactive protein complexes with the complement system. I. Consumption of human complement associated with the reaction of C-reactive protein with pneumococcal C-polysaccharide and with the choline phosphatides, lecithin and sphingomyelin. J Immunol 1974;112:2135–47.
   PubMed Web of Science ®Google Scholar
• Ma YJ, Garred P. Pentraxins in complement activation and regulation. Front Immunol 2018;9:3046.
   PubMed Web of Science ®Google Scholar
• Haapasalo K, Meri S. Regulation of the complement system by Pentraxins. Front Immunol 2019;10:1750.
   PubMed Web of Science ®Google Scholar
• Kozma GT, Mészáros T, Bakos T, Hennies M, Bencze D, Uzonyi B, et al. Mini-Factor H modulates complement-dependent IL-6 and IL-10 release in an immune cell culture (PBMC) Model: potential benefits against cytokine storm. Front Immunol 2021;12:642860.
   PubMed Web of Science ®Google Scholar
• Henwick S, Hetherington SV, Patrick CC. Complement binding to Aspergillus conidia correlates with pathogenicity. J Lab Clin Med 1993;122:27–35.
   PubMed Web of Science ®Google Scholar
• Suankratay C, Mold C, Zhang Y, Potempa LA, Lint TF, Gewurz H. Complement regulation in innate immunity and the acute-phase response: inhibition of mannan-binding lectin-initiated complement cytolysis by C-reactive protein (CRP). Clin Exp Immunol 1998;113:353–9.
   PubMed Web of Science ®Google Scholar
• Unizony S, Morris R, Kreuzer J, Haas W, Stone J. Mass spectrometry identifies novel biomarkers in giant cell arteritis, useful in patients on interleukin-6 receptor blockade (abstract). Arthritis Rheumatol 2020;72.
   Web of Science ®Google Scholar
• Reichenbach S, Adler S, Bonel H, Cullmann JL, Kuchen S, Bütikofer L, et al. Magnetic resonance angiography in giant cell arteritis: results of a randomized controlled trial of tocilizumab in giant cell arteritis. Rheumatology (Oxford) 2018;57:982–6.
   PubMed Web of Science ®Google Scholar
• De Boysson H, Aide N, Liozon E, Lambert M, Parienti JJ, Monteil J, et al. Repetitive 18F-FDG-PET/CT in patients with large-vessel giant-cell arteritis and controlled disease. Eur J Intern Med 2017;46:66–70.
   PubMed Web of Science ®Google Scholar